



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:  
Atef Gayed

Serial No.: 10/031,947

Filed: May 15, 2002

For: MULTI-DOSE ERYTHROPOIETIN  
FORMULATIONS

Group Art Unit: 1646


Examiner: Unknown

Atty. Dkt. No.: MAR618/4-005(A)US

CERTIFICATE OF MAILING  
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Mail Stop Fee Amendment, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450, on the date below:

March 28, 2005  
Date

  
Timothy S. Corder

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

MAIL STOP FEE AMENDMENT

Commissioner for Patents

P. O. Box 1450

Alexandria, VA 22313-1450


Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the document listed on the attached Form 1449 (Reference D6) be considered by the Examiner and made of record. The indicated reference was previously submitted with the inventor's name shown incorrectly. The enclosed Form 1449 form correctly indicates the inventor's name as Miyake. A copy of each Reference D9 and D10, previously submitted on December 11, 2003, are enclosed for the Examiner's review.

In accordance with 37 C.F.R. §§ 1.97(g),(h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. §1.97(d), the present Supplemental Information Disclosure Statement is being filed before payment of the issue fee. The fee as set forth in 37 C.F.R. § 1.17(p) for submission of an Information Disclosure Statement is also enclosed. If the referenced Credit Card Payment Form is inadvertently omitted or deficient, or should an overpayment be included herein, the Commissioner is authorized to appropriately deduct or credit the requisite amount from Vinson & Elkins L.L.P. deposit account No. 22-0365/MAR618/4-005(A)US/75000.

Respectfully submitted,



Timothy S. Corder  
Reg. No. 38,414  
Agent for Applicant

Vinson & Elkins L.L.P.  
2300 First City Tower  
1001 Fannin Street  
Houston, Texas 77002-6760  
512.542.8446

Date: March 28, 2005

553505\_1.DOC

# INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

APR 01 2005

Docket Number (Optional)

MAR618/4-005(A)US

Application Number

10/031,947

Applicant(s)

Atef Gayed

Filing Date

May 15, 2002

Group Art Unit

1646

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

D9	Drug Facts and Comparisons 2000, 54th ed., pp. 698, 1319, 1330.
D10	The Merck Index, 11th ed., pp. 7228 and 1084 (1989).
D11	Miyake, et al., "Purification of Human Erythropoietin," <i>J. Biol. Chem.</i> , 252(15):5558-67 (1997).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.